文献速递泌尿男性生殖肿瘤

局限前列腺癌中雄激素剥夺治疗与外照射放疗的时序:III期随机对照试验

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2019-12-12

这项III期随机对照试验纳入432例新诊断局限前列腺癌患者,比较ADT新辅助起始(放疗前4个月开始,共6个月)与同步起始(放疗同时开始,共6个月)联合剂量递增前列腺放疗的疗效与毒性。晚期≥3级胃肠及泌尿生殖毒性亦无显著差异。结论认为两种ADT起始方式均为合理的标准治疗选择。

要点

  • 3年晚期≥3级胃肠及泌尿生殖毒性两组相近,同步组bRFS HR为0.66(95%CI 0.41-1.07)。

核心结论

  • 局限前列腺癌中短期ADT新辅助或同步起始联合剂量递增前列腺放疗,在bRFS、OS及晚期放疗相关毒性上均无统计学显著差异。
  • 基于该结果,两种ADT起始方式均可视为局限前列腺癌的合理标准治疗。

研究设计与样本

  • III期随机对照试验,纳入新诊断局限前列腺癌患者432例,随机分为新辅助组(n=215)与同步组(n=217)。
  • 入组条件为Gleason评分≤7、临床分期T1b至T3a、前列腺特异性抗原<30 ng/mL。
  • 新辅助组ADT于放疗前4个月开始、共6个月;同步组ADT与放疗同时开始、共6个月;主要终点为生化复发无生存(bRFS)。

主要发现

  • 同步组相对新辅助组的bRFS风险比为0.66(95%CI 0.41-1.07),OS风险比为0.94(95%CI 0.68-1.30)。
  • 3年晚期放疗相关≥3级胃肠毒性发生率分别为2.5%与3.9%,泌尿生殖毒性均为2.9%,无显著差异。

关键数值与推荐

  • 晚期放疗相关≥3级毒性发生率采用log-rank检验比较。

临床怎么用

  • 对于符合入组条件的局限前列腺癌患者,临床可选择ADT新辅助起始(放疗前4个月开始,共6个月)或同步起始(与放疗同时开始,共6个月)联合剂量递增前列腺放疗。
  • 两种时序在疗效与晚期毒性上无显著差异,决策时可结合患者具体情况与放疗排程个体化选择。

局限性

  • 摘要未报告研究的具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing of these therapies is unclear. Our phase III trial compared neoadjuvant versus concurrent initiation of ADT in combination with dose-escalated prostate RT (PRT). PATIENTS AND METHODS: Patients with newly diagnosed LPCa with Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated to neoadjuvant and concurrent ADT for 6 months starting 4 months before RT (neoadjuvant group) or concurrent and adjuvant ADT for 6 months starting simultaneously with RT (concurrent group). The primary end point was biochemical relapse-free survival (bRFS). Stratified log-rank test was used to compare bRFS and overall survival (OS). Incidence of grade ≥ 3 late RT-related toxicities was compared by log-rank test. RESULTS: Overall, 432 patients were randomly assigned to the neoadjuvant (n = 215) or concurrent group (n = 217). At 10 years, bRFS rates for the two groups were 80.5% and 87.4%, respectively. Ten-year OS rates were 76.4% and 73.7%, respectively. There was no significant difference in bRFS (P = .10) or OS (P = .70) between the two groups. Relative to the neoadjuvant group, the hazard ratio for the concurrent group was 0.66 (95% CI, 0.41 to 1.07) for bRFS and 0.94 (95% CI, 0.68 to 1.30) for OS. No significant difference was observed in the 3-year incidence of late RT-related grade ≥ 3 GI (2.5% v 3.9%) or genitourinary toxicity (2.9% v 2.9%). CONCLUSION: In our study, there was no statistically significant difference in bRFS between the two treatment groups. Similarly, no difference was seen in OS or late RT-related toxicities. On the basis of these results, both neoadjuvant and concurrent initiations of short-term ADT with dose-escalated PRT are reasonable standards of care for LPCa.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Malone S, Roy S, Eapen L, et al. Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2019. PMID: 31829912. doi:10.1200/JCO.19.01904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。